Morgan Stanley Maintains HCA Healthcare(HCA.US) With Hold Rating, Maintains Target Price $355
Cautious Hold Rating on HCA Healthcare Amid Policy Uncertainties and Market Fluctuations
KeyBanc Adjusts HCA Healthcare's Price Target to $370 From $420, Maintains Overweight Rating
KeyBanc Lowers Price Target on HCA Healthcare to $370 From $420, Keeps Overweight Rating
KeyBanc Maintains HCA Healthcare(HCA.US) With Buy Rating, Cuts Target Price to $370
Truist Financial Maintains HCA Healthcare(HCA.US) With Buy Rating, Announces Target Price $390
HCA Healthcare Analyst Ratings
Optimistic Outlook and Buy Rating for HCA Healthcare Driven by Strategic Initiatives and Market Dynamics
HCA Healthcare Is Maintained at Equal-Weight by Morgan Stanley
Goldman Sachs Maintains HCA Healthcare(HCA.US) With Hold Rating, Cuts Target Price to $319
Morgan Stanley Maintains HCA Healthcare(HCA.US) With Hold Rating, Cuts Target Price to $355
HCA Healthcare Price Target Announced at $380.00/Share by JP Morgan
HCA Healthcare Analyst Ratings
Goldman Sachs Adjusts Price Target on HCA Healthcare to $319 From $359, Maintains Neutral Rating
J.P. Morgan Maintains HCA Healthcare(HCA.US) With Hold Rating, Raises Target Price to $380
Wells Fargo Downgrades HCA Healthcare(HCA.US) to Sell Rating, Cuts Target Price to $320
Wells Fargo Downgrades HCA Healthcare to Underweight From Equalweight, Adjusts Price Target to $320 From $400
HCA Healthcare Analyst Ratings
Raymond James Downgrades HCA Healthcare(HCA.US) to Hold Rating
BofA Securities Maintains HCA Healthcare(HCA.US) With Buy Rating